Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Proposed combination enhances Pfizer’s position as a leading company in oncology
Subscribe To Our Newsletter & Stay Updated